Market Newsdesk

Shenzhen, P.R. China , Dec. 23, 2025 (GLOBE NEWSWIRE) — Baiya International Group Inc. (NASDAQ: BIYA; the “Company” or “BIYA”), a human resource (“HR”) technology company utilizing its cloud-based internet platform to provide one-stop crowdsourcing recruitment and SaaS-enabled HR solutions is reporting that its board of directors has approved a reverse stock split (the “Reverse Stock Split”) of the Company’s class A ordinary shares, a par value of US$0.0001 each (the “Ordinary Shares”), at a ratio of 1-for-25, with a post-Reverse Stock Split par value of US$0.0025.

The Company is undertaking the Reverse Stock Split with the objective of meeting the minimum $1.00 per Ordinary Share bid requirement for maintaining the listing of the Ordinary Shares on The Nasdaq Capital Market.

The Reverse Stock Split will be effective at 04:01 p.m. (ET) on Monday, December 29, 2025 (the “Record Date”) and the Ordinary Shares will begin trading on a split-adjusted basis when the Nasdaq Stock Market LLC opens for trading on Tuesday, December 30, 2025. The Ordinary Shares will continue to trade on The Nasdaq Capital Market under the trading symbol “BIYA” but will trade under the following new CUSIP number: G51400151.

The number of the Company’s pre-Reverse Stock Split outstanding shares is 29,644,605 Ordinary Shares. As a result of the Reverse Stock Split, every 25 Ordinary Shares held as of the Record Date will be automatically combined into one Ordinary Share. The number of outstanding Ordinary Shares will be reduced from approximately from 29,644,605 Ordinary Shares to approximately 1,185,784 Ordinary Shares. No fractional shares will be created or issued in connection with the reverse stock split. The Reverse Stock Split will affect all holders of Ordinary Shares uniformly.

Shareholders with Ordinary Shares held in book-entry form or through a bank, broker, or other nominee are not required to take any action and will see the impact of the Reverse Stock Split reflected in their accounts on or after December 30, 2025. Such beneficial holders may contact their bank, broker, or nominee for more information.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The forward-looking statements can be also identified by terminology such as “may,” “might,” “could,” “will,” “aims,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements.

These forward-looking statements are based on our current assumptions, expectations and beliefs and involve substantial risks and uncertainties that may cause results, performance or achievement to materially differ from those expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to a number of risks. The reader should not place undue reliance on these forward-looking statements, as there can be no assurances that the plans, initiatives or expectations upon which they are based will occur. A detailed discussion of factors that could cause or contribute to such differences and other risks that affect our business is included in filings we make with the Commission from time to time, including our most recent report on Form 20-F, particularly under the heading “Risk Factors”.

For investor and media inquiries, please contact:

Baiya International Group Inc.

Investor Relations Department

Phone: +86 0769-88785888
Email: [email protected]
  
Investor Relations Inquiries:

Ascent Investor Relations LLC

Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]

Hauppauge, NY, Dec. 23, 2025 (GLOBE NEWSWIRE) — Cemtrex, Inc. (NASDAQ: CETX, CETXP) (the “Company”), an advanced security technology and industrial services company, today announced that it has entered into a definitive agreement for the purchase of approximately 800,000 shares and / or pre funded warrants with a single institutional investor, at a purchase price of $2.50 per share, with gross proceeds to the Company expected to be $2 million to the Company.

The transaction is expected to close on or about Dec 23, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering, for general corporate purposes, including working capital and potential acquisitions.

The offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-283995) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on February 3, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov.

Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cemtrex, Inc.

Cemtrex, Inc. (Nasdaq: CETX) is a diversified technology company operating in the Security and Industrial sectors. Its Security segment, led by Vicon Industries, provides advanced video management software, high-performance security cameras, and integrated surveillance solutions for enterprise, government, and critical infrastructure. The Industrial segment, through Advanced Industrial Services (AIS), delivers expert rigging, millwrighting, process piping, and equipment installation services to manufacturers nationwide. With a focus on innovation, execution, and strategic growth, Cemtrex is committed to enhancing safety, efficiency, and value for its customers and shareholders.

For more information visit www.cemtrex.com.

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Investor Relations 

[email protected]

– TrinScreen HIV order signals renewed strength in global HIV testing market

– Company also reports a key milestone of Adjusted EBITDA¹positive operations in Q3 2025 and expects to achieve strong additional profitability growth in Q1 and Q2 2026 through continued strong execution on its Comprehensive Transformation Plan

DUBLIN, Dec. 23, 2025 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has received an order for 9 million units of its flagship HIV screening product, TrinScreen HIV. This significant order marks a pivotal moment in the recovery and strengthening of the global health market for HIV testing, following disruptions earlier this year due to changes affecting international aid funding structures. In addition, the Company provided a trading update for its most recent financial quarters.

TrinScreen HIV Order

The order reflects a renewed commitment from global health organizations to support HIV screening efforts, particularly in regions most affected by the disease. Trinity Biotech’s TrinScreen HIV test is a WHO-prequalified, rapid diagnostic test designed for high-volume screening programs, offering reliable results and ease of use in diverse clinical settings.

Trinity Biotech will produce the tests through its recently WHO-approved outsourced manufacturing process, which allows for efficient and cost-effective scalability. The company anticipates fulfilling the order during the fourth quarter of 2025 and the first quarter of 2026, as it fine-tunes its manufacturing and supply chain to accommodate this significant rise in demand.

This order is expected to positively impact Trinity Biotech’s revenue and profitability outlook and underscores the Company’s strategic positioning in the global infectious disease diagnostics market.

Trading Update

• Revenues for Q3 2025 increased by 32% to $14.3m compared to $10.8m in Q2 2025, primarily due to:
  • A strong increase of $2.1m in rapid HIV test sales to $3.6m in Q3 2025, driven by renewed UniGold™ HIV rapid test demand and the resumption of TrinScreen HIV sales under the new manufacturing model; and
  • A significant rise in haemoglobin product sales, rising to $5.7m compared to $4.0m in Q2 2025.
• Gross profit for Q3 2025 was $6.5m compared to $4.6m in Q2 2025 driven by higher sales and an increase in gross margin from 42.6% to 45.2% supported by changes to the Company’s operating structure under its Comprehensive Transformation Plan.
• Adjusted EBITDA¹ of $0.5 million for Q3 2025 compared to negative $2.1m for Q2 2025.
• The Company has issued full presentations of its Q2 2025 and Q3 2025 results which can be viewed on the Company’s website www.trinitybiotech.com/investor-relations/financial-reports.

Trading Outlook

• The Company continues to make substantial progress in its Comprehensive Transformation Plan, having recently secured several critical regulatory approvals, including WHO authorization for outsourcing and offshoring the production of its Uni-Gold™ HIV rapid test.
• The receipt of these regulatory approvals allows the Company to proceed with the final core components of its Comprehensive Transformation Plan. These initiatives will be prioritised during the fourth quarter of 2025 and the first quarter of 2026, with the objective of realising additional efficiencies and further enhancing EBITDA performance.
• Consequently, the Company expects an increase in Adjusted EBITDA¹ throughout the first and second quarters of 2026 as it achieves these important operational restructuring milestones within its Comprehensive Transformation Plan.

Pipeline Developments

• The Company remains committed to pursuing immediate growth opportunities that are both profitable and supported by its streamlined, more adaptable operating base. This includes ongoing expansion into international markets with its latest product offerings:
  • An enhanced HbA1c testing solution for diabetes care;
  • Extending the availability of its TrinScreen HIV tests to new countries.
• The Company is also advancing the commercialisation of its key strategic growth projects currently in development, including:
  • Its next-generation continuous glucose monitor, CGM+;
  • EpiCapture, the company’s PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to more aggressive forms of the disease; and
  • PrePsia™, an innovative early pregnancy screening test designed to assess the risk of preeclampsia—a potentially life-threatening condition for both mother and baby.

John Gillard, CEO of Trinity Biotech, commented:

“We are delighted to have received this TrinScreen order. It represents a strong endorsement of our product’s quality and the trust global health partners place in Trinity Biotech.

Our operating and financial improvement in Q3 2025 was encouraging, in particular the achievement of positive Adjusted EBITDA

¹

. This gives us confidence that our Comprehensive Transformation Plan is on track and, when combined with our exciting innovation agenda, leaves the business well positioned for further progress in 2026.”

Management Transition

The Company announces that Susan O’Connor has completed her term as interim Chief Financial Officer, and Paul Murphy, Head of Group Reporting, has been promoted to the role of Interim Chief Financial Officer. The Company expresses its gratitude to Ms. O’Connor for her service and extends best wishes for her future endeavors.

Use of Non-IFRS Financial Measures

The Company’s unaudited financial statements were prepared in accordance with International Financial Reporting Standards (IFRS). To supplement the consolidated financial statements presented in accordance with IFRS, the Company presents non-IFRS presentations of EBITDA and Adjusted EBITDA. The adjustments to the Company’s IFRS results are made with the intent of providing both management and investors a more complete understanding of the Company’s underlying operational results, trends, and performance. Non-IFRS financial measures mainly exclude, if and when applicable, the effect of share-based compensation charges, depreciation, amortization and impairment charges.

EBITDA and Adjusted EBITDA is presented to evaluate the Company’s financial and operating results on a consistent basis from period to period. The Company also believes that these measures, when viewed in combination with the Company’s financial results prepared in accordance with IFRS, provides useful information to investors to evaluate ongoing operating results and trends. EBITDA and Adjusted EBITDA, however, should not be considered as an alternative to operating income or net income for the period and may not be indicative of the historic operating results of the Company; nor is it meant to be predictive of potential future results. EBITDA and Adjusted EBITDA are not measures of financial performance under IFRS and may not be comparable to other similarly titled measures for other companies. Reconciliation between the Company’s operating profit/(loss) and EBITDA and Adjusted EBITDA are presented with the Company’s financial results available on the Company’s website, www.trinitybiotech.com/investor-relations/financial-reports.

Forward-Looking Statements

This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, our ability to reduce our debt and improve our capitalization, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.

About Trinity Biotech

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. Our current products are used to detect a variety of health conditions including autoimmune, infectious and sexually transmitted diseases, and quantify the level of HbA1c in human blood. In January of 2024, we entered into the biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and we are currently developing a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide.

For further information, please see the Company’s website: www.trinitybiotech.com.

¹ Earnings before interest, tax, depreciation, amortisation, and share-based compensation charges – also excludes impairment charges, restructuring costs and non-recurring corporate finance and transaction-related costs.

SAN DIEGO, Dec. 23, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Cogent Communications Holdings, Inc. (NASDAQ: CCOI) focused on whether Cogent Communications and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

If you have information that could assist in the Cogent Communications investigation or if you are a Cogent Communications investor who suffered a loss and would like to learn more, you can provide your information here:

https://www.rgrdlaw.com/cases-cogent-communications-holdings-inc-investigation-ccoi.html

You can also contact attorneys

J.C. Sanchez

or

Jennifer N. Caringal

of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

.

THE COMPANY: Cogent Communications provides high-speed internet access, private network, and data center colocation space services.

THE REVELATION: On November 6, 2025, Cogent Communications reported third quarter of 2025 financial results, revealing service revenue year-over-year decrease of nearly 6%. Cogent also disclosed that it would cut its dividend by 98%, from $1.015 per share the prior quarter to $0.02 per share. After this news, the price of Cogent Communications shares fell nearly 35%.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez, Jennifer N. Caringal
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]

WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current chief executive officer of Collegium Pharmaceutical and having spent nearly a decade leading several lines of business and functions at Horizon Therapeutics.

“We are pleased to welcome Vikram to our Board as we advance toward commercialization,” said Jason Rhodes, chairman of Dyne’s Board of Directors and partner at Atlas Venture. “As a CEO and former commercial leader of a biotechnology company that grew quickly and successfully, Vikram brings valuable experience in launching products, driving growth, and realizing value. His insights will further Dyne’s progress toward generating revenue and expanding our portfolio.”

“Throughout my career, I’ve focused on translating innovation into highly successful businesses that unlock value and improve the lives of patients,” said Vikram Karnani. “Dyne’s clinically validated drug delivery approach and progress towards commercialization underscore its potential to deliver meaningful functional improvement for people living with neuromuscular diseases. I’m excited to join the Board at this pivotal stage as the company works to realize its full potential and build shareholder value.”

“Vikram’s track record of running world-class commercial and medical organizations will add an important perspective to our Board as we prepare for our first potential launch in Q1 2027,” said John Cox, president and chief executive officer of Dyne. “His experience leading rare disease portfolios, particularly through periods of rapid growth, aligns exceptionally well with our goal of building a commercial company with multiple opportunities to create value and potentially transform care for neuromuscular diseases.”

Mr. Karnani has served as president and chief executive officer of Collegium Pharmaceutical since November 2024. Collegium is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, with a leading portfolio in responsible pain management and a growing neuropsychiatry business. Prior to joining Collegium, he was executive vice president and president, global commercial operations and medical affairs (rare disease) at Amgen where he led the integration and growth of the company’s approximately $4 billion rare disease business following the $28 billion acquisition of Horizon Therapeutics. During nearly a decade at Horizon, Mr. Karnani held multiple senior executive roles, including president of global commercial operations and chief commercial officer, where he helped transform the company from a $500 million in revenue enterprise into a rare disease leader generating more than $3 billion in revenue through disciplined strategy, M&A, capital deployment and commercialization. Earlier in his career, Mr. Karnani served as vice president of the therapeutics and cell therapy business and held leadership roles in strategy and business development at Fresenius Kabi. 

Mr. Karnani holds a bachelor’s degree in electrical engineering from the University of Mumbai, a master’s degree in electrical engineering from Case Western Reserve University and an MBA from Northwestern University’s Kellogg School of Management.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne’s strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE^TM platform, expectations regarding the timing and outcome of interactions with and submissions to global regulatory authorities and anticipated timelines for submission for regulatory approval and launch of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne’s ability to enroll patients in clinical trials; whether results from preclinical studies and initial data from early clinical trials will be predictive of the final results of the clinical trials or future trials; uncertainties as to the FDA’s and other regulatory authorities’ interpretation of the data from Dyne’s clinical trials and acceptance of Dyne’s clinical programs and the regulatory approval process, including the availability of accelerated approval pathways; whether Dyne’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.

Contacts:

Investors

Mia Tobias
[email protected]
781-317-0353

Media
Stacy Nartker
[email protected]
781-317-1938

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE: SLG), Manhattan’s largest office landlord, today announced that it will release its earnings for the fourth quarter of 2025 on Wednesday, January 28, 2026 after market close.

The Company’s executive management team, led by Marc Holliday, Chairman and Chief Executive Officer, will host a conference call and audio webcast on Thursday, January 29, 2026 at 2:00pm ET to discuss the financial results.

Simultaneous with the earnings release, supplemental data will be made available in the Investors section of the SL Green Realty Corp. website at https://slgreen.com under “Financial Reports”.

The live conference call will be webcast in listen-only mode and a replay will be available in the Investors section of the SL Green Realty Corp. website at https://slgreen.com under “Presentations & Webcasts”.

Research analysts who wish to participate in the conference call must first register at https://register-conf.media-server.com/register/BIdf54cb0f07f14525b86bd3b1dcc871fd.

About SL Green Realty Corp.

SL Green Realty Corp., Manhattan’s largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing the value of Manhattan commercial properties. As of September 30, 2025, SL Green held interests in 53 buildings totaling 30.7 million square feet. This included ownership interests in 27.1 million square feet of Manhattan buildings and 2.7 million square feet securing debt and preferred equity investments.

PRESS CONTACT
[email protected]

SLG-EARN